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In our recent research letter focusing on the acute effects of
smoking on the serum levels of sRAGE (soluble receptor for
advanced glycation end products), we showed that smoking three
cigarettes within 1 hour signiﬁcantly decreases serum sRAGE
levels within 2 hours (1). In addition, we also determined the
effect of chronic cigarette smoke exposure on serum sRAGE levels
by comparing smokers with never smokers (originally reported
as “data not shown”). Here, we did not ﬁnd any difference in
serum sRAGE levels, which is in line with previous studies (2).
In contrast, as rightfully mentioned in the response to our
research letter, Biswas and colleagues previously reported that
serum sRAGE levels were increased in smokers compared with
nonsmokers (3). Biswas explains the discrepancies between
their study and other studies by noting that most of the studies
were not speciﬁcally designed to explore the effect of smoking
on sRAGE in healthy individuals, whereas their study was (4).
Further, in his original paper, he states that the differences may
also be explained by the fact that his study population was of
overall younger age compared with those in the other studies (3).
Indeed, characteristics of the study population may affect the
outcomes of sRAGE measurements; however, other factors,
including the method and timing of serum preparation, the
method of sRAGE quantiﬁcation, and, most importantly, the
timing of the last smoked cigarette before blood sampling may
also drive the observed differences in serum sRAGE levels.
Although our initial research letter only showed data of serum
sRAGE levels in healthy control subjects versus patients with
chronic obstructive pulmonary disease (COPD) (1), our study
was also designed to investigate the chronic effects of smoking
in healthy individuals. Speciﬁcally, to investigate the effect of
chronic smoke exposure on the serum levels of sRAGE, we
used a well-controlled cohort (ClinicalTrials.gov Identiﬁer:
NCT00848406) of young (18–40 yr old) and old (.40 yr old)
smokers and never smokers without airway obstruction
(Figure 1A) (5). To adequately measure serum sRAGE
levels, we used the highly sensitive and selective simpliﬁed
immunoprecipitation in 96-well ELISA format–coupled liquid
chromatography–mass spectrometry assay, which we recently
demonstrated to be superior to the commonly used sRAGE ELISA
(6). When we focused on the healthy control subjects, we found
that there were no differences in serum sRAGE levels between
smokers and never smokers, whether old or young (Figure 1B).
Of note, the deﬁnition of “nonsmokers” in our study and
the one used by Biswas are not exactly the same. Whereas
our nonsmokers had never smoked, the nonsmokers in Biswas’s
study included subjects who had not smoked during the last
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Figure 1. Serum sRAGE (soluble receptor for advanced glycation end products) levels in never smokers and smokers. (A) Patient characteristics. BMI =
body mass index (kg/m2); N = number of group participants; sex (M) = number of males in a group. Data are shown as mean6 SEM. (B) Levels of sRAGE
were measured in serum of young (18–40 yr old) smokers (n = 26) and nonsmokers (n = 28), and age-matched old (.40 yr old) smokers (n = 28) and
nonsmokers (n = 28) without airway obstruction using immunoprecipitation in 96-well ELISA format–coupled liquid chromatography–mass spectrometry.
Data are shown as individual measurements and mean6 SEM.
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5 consecutive years. Moreover, the age of the study subjects does
not inﬂuence the serum sRAGE levels. Indeed, our data show no
differences in serum sRAGE levels between young (average 23.5 yr)
and old (average 54.7 yr) subjects in either the never-smokers group or
the smokers group (Figure 1B). In addition, our young subjects were
even younger than the study population of Biswas, which had an
average age of 34.1 years. Our data therefore indicate that neither
age nor chronic smoke exposure affects serum sRAGE levels. The
discrepancy in study results when comparing the serum sRAGE levels
in smokers and nonsmokers may be explained by our ﬁnding that
smoking before blood sampling acutely decreases serum sRAGE levels
(1). Therefore, controlling or monitoring smoking behavior before
blood sampling may be used as a precautionary measure to decrease
the variability between measurements and increase the value of
sRAGE as a biomarker for COPD. Lastly, we agree with Biswas that
more research is needed regarding the effect of smoking on serum
sRAGE levels and the underlying mechanisms before sRAGE can be
clinically used as a biomarker for COPD. n
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Socioeconomic Disparities and Health Outcomes
To the Editor:
The ability to link data from sources such as the U.S. Census is
now enabling researchers to direct their focus toward reporting
neighborhood and contextual characteristics that increase the risk for
adverse health outcomes and are independent of patient-level attributes.
This is all the more important because disparities in health outcomes
likely arise as a result of both individual exposures and contextual
factors (1). Research regarding disparities have until recently been
challenging because of the high response bias associated with
collecting individual-level socioeconomic measures (2). However,
area-based measures from the U.S. Census’s American Community
Survey and the National Center for Health Statistics Urban-Rural
Classiﬁcation Scheme can be used to gain insight into the role of area-
based measures as independent risk factors for diseases, as
demonstrated in the work by Raju and colleagues (3). Understanding
area-based risk factors could help researchers design, target, monitor,
and assess public health programs, including prevention interventions.
First, some limitations of Raju and colleagues’ analysis
need to be emphasized. Although the authors used census tract–
based determinants as area-based measures, it is important to
acknowledge the possibility of ecological fallacy, and that these
determinants provide information regarding the neighborhood
that is not reducible to the individual level (4). Although the authors
have deﬁned neighborhoods as census tracts, nearby neighborhoods
may also inﬂuence health outcomes and disparities.
Second, data structures arising from both individual and
neighborhood levels are inherently hierarchical and correlated. To
account for geographical correlation, it is important to analyze such
data using multilevel models. Multilevel models can account for a lack
of independence, evaluate multivariate associations, incorporate
covariates at both individual and geographic levels, and model
interactions between variables (5). Multilevel models have been used
to evaluate health disparities and to describe the relationship
between geographic exposures for a wide variety of health outcomes.
They can also help researchers quantify the proportion of variability
associated with being in a speciﬁc neighborhood.
The authors are to be applauded for taking the research on chronic
obstructive pulmonary disease risk factors a step further by investigating
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